Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 1:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: QT Interval Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

NCT04867980
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ACP-196, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 2 Interventional

Defining The Role Of Dialysate Magnesium In Arrhythmogenicity On Dialysis

NCT00242164
View directory record Official record
Conditions
Chronic Kidney Disease, Arrhythmia
Interventions
Dialysate Magnesium (Concentration)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2014 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

NCT06649942
View directory record Official record
Conditions
Healthy Volunteers - Male and Female
Interventions
KP-001, Moxifloxacin 400 mg, Placebo
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

NCT04238195
View directory record Official record
Conditions
TQT Study
Interventions
Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr), Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)
Drug · Other
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

NCT03958123
View directory record Official record
Conditions
Prolonged QTc Interval, Pharmacokinetic
Interventions
100 μg cebranopadol, 200 μg cebranopadol, 400 μg cebranopadol, Placebo to cebranopadol encapsulated tablets, 400 mg Moxifloxacin, Placebo to moxifloxacin encapsulated tablets
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

NCT03985410
View directory record Official record
Conditions
Acinetobacter Baumannii-calcoaceticus Complex Infections
Interventions
ETX2514, Placebo, moxifloxacin
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 14, 2026, 1:51 AM EDT
Completed No phase listed Observational

QT Variability Pre and Post Cardioversion

NCT00885391
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
21 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

NCT05192369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CTP-543, Moxifloxacin, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

NCT05818852
View directory record Official record
Conditions
Pain
Interventions
VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

NCT00698841
View directory record Official record
Conditions
Advanced Cancer
Interventions
Cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Muscle Shoals, Alabama • Casa Grande, Arizona • Corona, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2015 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Carbetocin on the QT/QTc Interval in Healthy Subjects

NCT05924321
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Carbetocin, Placebo, Placebo and Moxifloxacin
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

NCT05867147
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CAEB071 Thorough QTc Study in Healthy Volunteers

NCT01594255
View directory record Official record
Conditions
Healthy
Interventions
sotrastaurin, placebo to sotrastaurin, Avelox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Results available

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

NCT01606436
View directory record Official record
Conditions
Schizophrenic Disorders
Interventions
LY2140023, Placebo, Moxifloxacin
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Garden Grove, California • San Diego, California • North Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

NCT06258265
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

NCT05988034
View directory record Official record
Conditions
Electrocardiography
Interventions
Avacopan, Moxifloxacin, Placebo for avacopan, Placebo for moxifloxacin
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 14, 2026, 1:51 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Odiparcil QT Definitive Study

NCT00437242
View directory record Official record
Conditions
Fibrillation, Atrial, Atrial Fibrillation
Interventions
Odiparcil
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Sep 14, 2026, 1:51 AM EDT
Completed No phase listed Observational Results available

QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)

NCT05488470
View directory record Official record
Conditions
Atrial Arrhythmia, QT Interval, Variation in, Arrhythmias, Cardiac
Interventions
LINQ/LINQ II
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Jacksonville, Florida • Columbus, Ohio • Coos Bay, Oregon
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

NCT01706679
View directory record Official record
Conditions
Healthy
Interventions
ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg), Placebo vehicle (PBS)
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT05924815
View directory record Official record
Conditions
Healthy Participants
Interventions
Aficamten, Aficamten-matching Placebo, Moxifloxacin
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers

NCT02910635
View directory record Official record
Conditions
Abnormalities, Cardiovascular
Interventions
Volanesorsen, Moxifloxacin, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers

NCT01689116
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bardoxolone Methyl 20mg, Bardoxolone Methyl 80mg, Bardoxolone Methyl Placebo, Moxifloxacin 400mg, Moxifloxacin Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 50 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

NCT00672984
View directory record Official record
Conditions
Healthy Volunteers
Interventions
immediate release guanfacine hydrochloride, moxifloxacin, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 14, 2026, 1:51 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

NCT01073163
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
36
States / cities
Tucson, Arizona • Little Rock, Arkansas • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 14, 2026, 1:51 AM EDT